Phase I open-label, multicenter, dose-escalation clinical study of the safety and pharmacokinetic profiles of weekly intravenous administrations of SNS-595 [voreloxin] in patients with advanced malignancies
Phase of Trial: Phase I
Latest Information Update: 09 May 2007
At a glance
- Drugs Vosaroxin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 08 Jan 2007 New trial record.